Event update - Hansa Biopharma

Analyst Comment

We hosted a Deep Dive Event yesterday with Elisabeth Sonesson - Global Franchise Lead Autoimmune Diseases. 
Learn more about this interesting rare disease company.

Elisabeth Sonesson deep dive into other indications for Imlifidase. Like Anti GBM, GBS and AMR. Why do Hansa expect Imlifidase to be better than the current plasma replacement therapy and are the regulatory bodies EMA/FDA ready to handle these new types of treatment. These and many other questions will Elisabeth Sonesson answer during her presentation.

Watch the interview here: https://www.inderes.dk/videos/hansa-biopharma-deep-dive-into-other-indications-for-imlifidase


HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 07:10 AM 05-31-2023.